{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:47:50Z","timestamp":1793011670253,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["201210388-3"],"award-info":[{"award-number":["201210388-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["201221513-3"],"award-info":[{"award-number":["201221513-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejpb.2017.02.020","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T02:24:55Z","timestamp":1488335095000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy"],"prefix":"10.1016","volume":"115","author":[{"given":"Josimar O.","family":"Eloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Petrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deise L.","family":"Chesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano P.","family":"Saggioro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Maldonado","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2017.02.020_b0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10552-016-0726-5","article-title":"Breast cancer survival among young women: a review of the role of modifiable lifestyle factors","volume":"27","author":"Brenner","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejpb.2017.02.020_b0010","article-title":"Consequences of the convergence of multiple alternate pathways on the estrogen receptor in the treatment of metastatic breast cancer","author":"Gl\u00fcck","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejpb.2017.02.020_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.breast.2016.09.002","article-title":"Tumor microenvironment-mediated chemoresistance in breast cancer","volume":"30","author":"Samadi","year":"2016","journal-title":"The Breast"},{"issue":"1","key":"10.1016\/j.ejpb.2017.02.020_b0020","first-page":"7","volume":"66","author":"Siegel","year":"2016","journal-title":"Cancer Stat."},{"key":"10.1016\/j.ejpb.2017.02.020_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.breast.2016.07.026","article-title":"Current and emerging therapies of HER2-positive metastatic breast cancer","volume":"29","author":"Hern\u00e1ndez-Blanquisett","year":"2016","journal-title":"The Breast"},{"key":"10.1016\/j.ejpb.2017.02.020_b0030","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-016-4002-x","article-title":"Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: a systematic review and meta-analysis","author":"Hervik","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejpb.2017.02.020_b0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.phrs.2016.07.023","article-title":"Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer","volume":"111","author":"Bakrania","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2017.02.020_b0040","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejpb.2017.02.020_b0045","first-page":"353","article-title":"Biochimica et Biophysica Acta Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer","volume":"1846","author":"Vu","year":"2014","journal-title":"BBA \u2013 Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejpb.2017.02.020_b0050","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/mt.2014.27","article-title":"Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K\/Akt\/mTOR pathway","volume":"22","author":"Blanco","year":"2014","journal-title":"Mol. Therapy"},{"issue":"5","key":"10.1016\/j.ejpb.2017.02.020_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.breast.2015.06.002","article-title":"Potential of overcoming resistance to HER2-targeted therapies through the PI3K\/Akt\/mTOR pathway","volume":"24","author":"Wilks","year":"2015","journal-title":"The Breast"},{"key":"10.1016\/j.ejpb.2017.02.020_b0060","first-page":"79","article-title":"European Journal of Pharmaceutical Sciences Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel","volume":"83","author":"Yin","year":"2016","journal-title":"PHASCI"},{"key":"10.1016\/j.ejpb.2017.02.020_b0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.colsurfa.2016.05.017","article-title":"Rapamycin-loaded solid lipid nanoparticles: Morphology and impact of the drug loading on the phase transition between lipid polymorphs","volume":"502","author":"Giovagnoli","year":"2016","journal-title":"Colloids Surf. A: Physicochem. Eng. Aspects"},{"key":"10.1016\/j.ejpb.2017.02.020_b0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.colsurfb.2016.09.020","article-title":"Tumor targeting strategies for chitosan-based nanoparticles","volume":"148","author":"Zhang","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ejpb.2017.02.020_b0075","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: a comprehensive review of the literature","author":"Bazak","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2017.02.020_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation","volume":"338","author":"Yang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.02.020_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/629234","article-title":"A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect","volume":"2011","author":"Kan","year":"2011","journal-title":"J. Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.02.020_b0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2011.04.055","article-title":"Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis","volume":"414","author":"Haeri","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.02.020_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.colsurfb.2016.01.032","article-title":"Co-loaded paclitaxel\/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy","volume":"141","author":"Eloy","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.02.020_b0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijpharm.2016.09.067","article-title":"Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells","volume":"513","author":"Noh","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2017.02.020_b0105","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s11095-007-9425-y","article-title":"Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells","volume":"24","author":"Yang","year":"2007","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2017.02.020_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1871520616666160526103432","article-title":"Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells","volume":"17","author":"Eloy","year":"2017","journal-title":"Anti-Cancer Agents Med. Chem. (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"10.1016\/j.ejpb.2017.02.020_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbamem.2005.02.007","article-title":"Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity","volume":"1711","author":"Laginha","year":"2005","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"10.1016\/j.ejpb.2017.02.020_b0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2007.05.011","article-title":"Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome","volume":"120","author":"Yang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.02.020_b0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.carbpol.2014.04.038","article-title":"Layer-by-layer assembly of chitosan stabilized multilayered liposomes for paclitaxel delivery","volume":"111","author":"Chen","year":"2014","journal-title":"Carbohyd. Polym."},{"key":"10.1016\/j.ejpb.2017.02.020_b0130","doi-asserted-by":"crossref","DOI":"10.1021\/ja507255g","article-title":"The disaccharide moiety of bleomycin facilitates uptake by cancer cells","author":"Schroeder","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2017.02.020_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative dose-effect relationships: the combined effects of multiple","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejpb.2017.02.020_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/209205","article-title":"Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme","volume":"2013","author":"Mortensen","year":"2013","journal-title":"J. Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejpb.2017.02.020_b0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-008-9916-5","article-title":"Therapeutic metformin\/AMPK activation promotes the angiogenic phenotype in the ER\u03b1 negative MDA-MB-435 breast cancer model","volume":"113","author":"Phoenix","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ejpb.2017.02.020_b0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors : Myths, reality and possibility","volume":"153","author":"Han","year":"2011","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejpb.2017.02.020_b0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.02.020_b0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.09.010","article-title":"Selective death of human breast cancer cells by lytic immunoliposomes: correlation with their HER2 expression level","volume":"290","author":"Barraj\u00f3n-catal\u00e1n","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2017.02.020_b0165","doi-asserted-by":"crossref","DOI":"10.1021\/mp400122m","article-title":"Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade","author":"Mishra","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.02.020_b0170","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-009-0715-4","article-title":"Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells","author":"Burks","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ejpb.2017.02.020_b0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","article-title":"ScienceDirect A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.02.020_b0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0168-3659(01)00315-7","article-title":"Tumor targeting using anti-her2 immunoliposomes","volume":"74","author":"Park","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.02.020_b0185","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/cncr.25120","article-title":"Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer","volume":"2","author":"Chang","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejpb.2017.02.020_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3618","article-title":"Clinical development of mTOR inhibitors in breast cancer","volume":"16","author":"Vicier","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"34","key":"10.1016\/j.ejpb.2017.02.020_b0195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2017.02.020_b0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10549-013-2689-5","article-title":"A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy","author":"Hurvitz","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ejpb.2017.02.020_b0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2010.11.002","article-title":"Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor","volume":"150","author":"Manjappa","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.02.020_b0210","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.pharmthera.2013.03.004","article-title":"Monoclonal antibody-based therapies in cancer: advances and challenges","volume":"138","author":"Sapra","year":"2013","journal-title":"Pharmacol. Therapeutics"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964111630786X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964111630786X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:26:40Z","timestamp":1656937600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964111630786X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":42,"alternative-id":["S093964111630786X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.02.020","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}